Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12911144 | 0.88 | CMA1 (0.40) | CMA1MAOBMAPTNPC1RAB9A | |
| SCHEMBL12911148 | 0.85 | CMA1 (0.44) | CMA1MAOBMAPTNPC1RAB9A | |
| SCHEMBL5452793 | 0.85 | MAOB (0.43) | CMA1MAOBMAPTNPC1RAB9A | |
| SCHEMBL12911153 | 0.75 | PSMB5 (0.46) | CMA1MAOBMAPTPSMB5ADORA2B | |
| SCHEMBL12911134 | 0.74 | CMA1 (0.43) | CMA1MAOBMAPTNPC1RAB9A | |
| SCHEMBL12911128 | 0.74 | CMA1 (0.43) | CMA1MAOBMAPTNPC1RAB9A | |
| SCHEMBL29076119 | 0.71 | MAOB (0.48) | MAOBNQO1PTGESPTGS2PSMB5 | |
| SCHEMBL29076121 | 0.71 | MAOB (0.48) | MAOBNQO1PTGESPTGS2PSMB5 | |
| SCHEMBL12987640 | 0.71 | MAOB (0.56) | MAOBMAPTPSMB5PSMB8ALDH1A1 | |
| SCHEMBL12911156 | 0.70 | CA2 (0.43) | CMA1MAOBMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872044-B2 | (thio)amide benzofuran compounds containing phosphonic, phosphinic, sulfonic, sulfamic, or carboxy acid groups; for example [benzofuran-3-yl-(naphthalen-2-ylcarbamoyl)-methyl]-phosphonic acid; treating inflammatory or serine protease mediated disorders such as allergic rhinitis, asthma and heart failure | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-18 | — | — | US | disclosed |
| US-20080096844-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096844-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, PRSS1 | CMA1 1/4885MAOB 899/4885MAPT 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.